TXG Stock Analysis: Buy, Sell, or Hold?
TXG - 10x Genomics, Inc. Class A Common Stock
$19.81
0.33 (1.69%)
▲
5d:
+3.5%
30d:
-14.06%
90d:
+20.13%
BUY
MODERATE Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 14, 2026
Get Alerted When TXG Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: TXG shows positive signals but monitor for confirmation. Market pricing in 0.7% decline. Moderate conviction.
💡 BUY OPPORTUNITY: TXG shows positive signals but monitor for confirmation. Market pricing in 0.7% decline. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: TXG is currently trading at $19.81, which is considered fair relative to its 30-day fair value range of $18.28 to $21.57. The stock's valuation (Forward PE: 119.3) is in line with its historical norms (121.7). Remarkably, the market is currently pricing in an annual earnings decline of 0.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, TXG is in a uptrend. Immediate support is located at $16.69, while resistance sits at $21.20.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TXG is in a uptrend. Immediate support is located at $16.69, while resistance sits at $21.20.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$18.28 -
$21.57
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
67.6%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($20.15)
Fair Price Analysis
30-Day Fair Range
$18.28 -
$21.57
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$16.69
Resistance Level
$21.20
Current Trend
Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
119.29
Wall Street Target
$20.15
(+3.5%)
Revenue Growth (YoY)
0.6%
Profit Margin
-6.8%
Valuation Discount vs History
-0.7% cheaper
PE vs Historical
119.3 vs 121.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.7%
(market-implied from PE analysis)
1-Year Target
$19.34
(-1%)
2-Year Target
$19.21
(-1%)
3-Year Target
$19.07
(-2%)
3-Yr Target (if PE normalizes)
(PE: 119→122)
$19.46
(0%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 119.3 to 121.7
Stabilization Target:
$19.87
(+2.0%)
PE Expansion Potential:
+2.0%
Share & Embed Analysis
Last updated: March 30, 2026 4:56 PM ET
Data refreshes hourly during market hours. Next update: 5:56 PM
Data refreshes hourly during market hours. Next update: 5:56 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TXG showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Adam Taich
SELL
8968 shares
2026-02-23
Benjamin J Hindson
SELL
7826 shares
2026-02-23
Serge Saxonov
SELL
9632 shares
2026-02-23
Top Rated Health Information Services Stocks
Top-rated stocks in Health Information Services by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VEEV
Veeva Systems Inc Class A |
BUY
32 analysts |
$271 | 50 HOLD |
|
PRVA
Privia Health Group Inc |
STRONG BUY
21 analysts |
$32 | 54 HOLD |
|
GEHC
GE HealthCare Technologi… |
STRONG BUY
21 analysts |
$90 | 59 HOLD |
|
PHR
Phreesia Inc |
STRONG BUY
15 analysts |
$28 | 58 HOLD |
|
HQY
HealthEquity Inc |
STRONG BUY
14 analysts |
$112 | 61 BUY |
